Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y, Ho MN, Jiang J, Kirk CJ, Laidig GJ, Lewis ER, Lu Y, Muchamuel T, Parlati F, Ring E, Shenk KD, Shields J, Shwonek PJ, Stanton T, Sun CM, Sylvain C, Woo TM, Yang J. Zhou HJ, et al. Among authors: demo sd. J Med Chem. 2009 May 14;52(9):3028-38. doi: 10.1021/jm801329v. J Med Chem. 2009. PMID: 19348473
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK. Demo SD, et al. Cancer Res. 2007 Jul 1;67(13):6383-91. doi: 10.1158/0008-5472.CAN-06-4086. Cancer Res. 2007. PMID: 17616698
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F, Bennett MK. Gross MI, et al. Among authors: demo sd. Mol Cancer Ther. 2014 Apr;13(4):890-901. doi: 10.1158/1535-7163.MCT-13-0870. Epub 2014 Feb 12. Mol Cancer Ther. 2014. PMID: 24523301
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, Kirk CJ. Suzuki E, et al. PLoS One. 2011;6(12):e27996. doi: 10.1371/journal.pone.0027996. Epub 2011 Dec 22. PLoS One. 2011. PMID: 22216088 Free PMC article.
Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.
Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, Issakani SD, Molineaux S, Demo SD. Pray TR, et al. Among authors: demo sd. Drug Resist Updat. 2002 Dec;5(6):249-58. doi: 10.1016/s1368-7646(02)00121-8. Drug Resist Updat. 2002. PMID: 12531181 Review.
Drug discovery in the ubiquitin regulatory pathway.
Wong BR, Parlati F, Qu K, Demo S, Pray T, Huang J, Payan DG, Bennett MK. Wong BR, et al. Drug Discov Today. 2003 Aug 15;8(16):746-54. doi: 10.1016/s1359-6446(03)02780-6. Drug Discov Today. 2003. PMID: 12944097 Review.
24 results